Ahmed Saadani Hassani1, Barbara J Marston. 1. *HIV Care and Treatment Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA; and †Emergency Response and Recovery Branch, Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
BACKGROUND: HIV-infected adults are at increased risk of severe malaria and death. Malaria prevention in people living with HIV (PLHIV) consists of several interventions, including cotrimoxazole (CTX) prophylaxis and insecticide-treated nets (ITNs). We conducted a systematic review of the available evidence. METHODS: MEDLINE, EmBase, Global Health, CINAHL, SOCA, and African Index Medicus were used to identify articles relevant to the CTX prophylaxis and ITNs interventions from 1995 to July 2014. For each individual study, we assessed the quality of evidence and the impact of the 2 interventions on the outcomes of mortality, morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. For each outcome, we summarized the quality of the overall body of evidence, the expected impact, and costing and cost-effectiveness (CE). FINDINGS: The overall quality of evidence regarding malaria-related morbidity was rated as "good" for CTX prophylaxis and "fair" for ITN use; the expected "impact" of these interventions on morbidity was rated "high" and "uncertain," respectively. Three studies that addressed the costing and CE of ITN provision for malaria prevention in PLHIV consisted of 2 full "level 1" and 1 partial "level 2" economic evaluations. CONCLUSIONS: CTX prophylaxis is effective in reducing malaria-related morbidity among PLHIV. Limited evidence is available with respect to the impact and the CE of ITN use and/or provision in this population.
BACKGROUND:HIV-infected adults are at increased risk of severe malaria and death. Malaria prevention in people living with HIV (PLHIV) consists of several interventions, including cotrimoxazole (CTX) prophylaxis and insecticide-treated nets (ITNs). We conducted a systematic review of the available evidence. METHODS: MEDLINE, EmBase, Global Health, CINAHL, SOCA, and African Index Medicus were used to identify articles relevant to the CTX prophylaxis and ITNs interventions from 1995 to July 2014. For each individual study, we assessed the quality of evidence and the impact of the 2 interventions on the outcomes of mortality, morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. For each outcome, we summarized the quality of the overall body of evidence, the expected impact, and costing and cost-effectiveness (CE). FINDINGS: The overall quality of evidence regarding malaria-related morbidity was rated as "good" for CTX prophylaxis and "fair" for ITN use; the expected "impact" of these interventions on morbidity was rated "high" and "uncertain," respectively. Three studies that addressed the costing and CE of ITN provision for malaria prevention in PLHIV consisted of 2 full "level 1" and 1 partial "level 2" economic evaluations. CONCLUSIONS:CTX prophylaxis is effective in reducing malaria-related morbidity among PLHIV. Limited evidence is available with respect to the impact and the CE of ITN use and/or provision in this population.
Authors: Ramanan Laxminarayan; Anne J Mills; Joel G Breman; Anthony R Measham; George Alleyne; Mariam Claeson; Prabhat Jha; Philip Musgrove; Jeffrey Chow; Sonbol Shahid-Salles; Dean T Jamison Journal: Lancet Date: 2006-04-08 Impact factor: 79.321
Authors: Eli Kern; Stéphane Verguet; Krista Yuhas; Frederick H Odhiambo; James G Kahn; Judd Walson Journal: Trop Med Int Health Date: 2013-05-10 Impact factor: 2.622
Authors: Sándor Bereczky; Anne Liljander; Ingegerd Rooth; Lea Faraja; Fredrik Granath; Scott M Montgomery; Anna Färnert Journal: Microbes Infect Date: 2006-12-06 Impact factor: 2.700
Authors: B M Greenwood; P H David; L N Otoo-Forbes; S J Allen; P L Alonso; J R Armstrong Schellenberg; P Byass; M Hurwitz; A Menon; R W Snow Journal: Trans R Soc Trop Med Hyg Date: 1995 Nov-Dec Impact factor: 2.184
Authors: Samuel S Malamba; Jonathan Mermin; Arthur Reingold; John R Lule; Robert Downing; Ray Ransom; Aminah Kigozi; Ben M Hunt; Alan Hubbard; Philip J Rosenthal; Grant Dorsey Journal: Am J Trop Med Hyg Date: 2006-09 Impact factor: 2.345
Authors: R W Steketee; J J Wirima; P B Bloland; B Chilima; J H Mermin; L Chitsulo; J G Breman Journal: Am J Trop Med Hyg Date: 1996 Impact factor: 2.345
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Mary J Hamel; Carolyn Greene; Tom Chiller; Peter Ouma; Christina Polyak; Kephas Otieno; John Williamson; Ya Ping Shi; Daniel R Feikin; Barbara Marston; John T Brooks; Amanda Poe; Zhiyong Zhou; Benjamin Ochieng; Eric Mintz; Laurence Slutsker Journal: Am J Trop Med Hyg Date: 2008-09 Impact factor: 2.345